NO2021023I1 - Somapacitan - Google Patents
SomapacitanInfo
- Publication number
- NO2021023I1 NO2021023I1 NO2021023C NO2021023C NO2021023I1 NO 2021023 I1 NO2021023 I1 NO 2021023I1 NO 2021023 C NO2021023 C NO 2021023C NO 2021023 C NO2021023 C NO 2021023C NO 2021023 I1 NO2021023 I1 NO 2021023I1
- Authority
- NO
- Norway
- Prior art keywords
- somapacitan
- Prior art date
Links
- NAKSIOUBFDBTSW-ITMZJIMRSA-N (2S)-5-[2-[2-[2-[[(2S)-1-amino-6-[[2-[(2R)-2-amino-2-carboxyethyl]sulfanylacetyl]amino]-1-oxohexan-2-yl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-[[(4S)-4-carboxy-4-[[2-[2-[2-[4-[17-(2H-tetrazol-5-yl)heptadec-1-en-2-ylsulfamoyl]butanoylamino]ethoxy]ethoxy]acetyl]amino]butanoyl]amino]-5-oxopentanoic acid Chemical compound N[C@@H](CSCC(=O)NCCCC[C@H](NC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CC[C@H](NC(=O)COCCOCCNC(=O)CCCS(=O)(=O)NC(=C)CCCCCCCCCCCCCCCc1nnn[nH]1)C(O)=O)C(O)=O)C(N)=O)C(O)=O NAKSIOUBFDBTSW-ITMZJIMRSA-N 0.000 title 1
- 229950005046 somapacitan Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151405 | 2010-01-22 | ||
PCT/EP2011/050923 WO2011089255A1 (en) | 2010-01-22 | 2011-01-24 | Growth hormones with prolonged in-vivo efficacy |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2021023I1 true NO2021023I1 (no) | 2021-05-26 |
Family
ID=42075933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2021023C NO2021023I1 (no) | 2010-01-22 | 2021-05-26 | Somapacitan |
Country Status (20)
Country | Link |
---|---|
US (5) | US9695226B2 (no) |
EP (1) | EP2525834B1 (no) |
JP (2) | JP5875527B2 (no) |
KR (1) | KR101813595B1 (no) |
CN (2) | CN103002918B (no) |
AU (1) | AU2011208625C1 (no) |
BR (1) | BR112012018116B1 (no) |
CA (1) | CA2787890C (no) |
FI (1) | FIC20210013I1 (no) |
FR (1) | FR21C1029I2 (no) |
HU (1) | HUS2100029I1 (no) |
IL (1) | IL220605A (no) |
MX (1) | MX345736B (no) |
NO (1) | NO2021023I1 (no) |
PL (1) | PL2525834T3 (no) |
RS (1) | RS59459B1 (no) |
RU (1) | RU2605627C2 (no) |
SI (1) | SI2525834T1 (no) |
TW (1) | TWI508737B (no) |
WO (1) | WO2011089255A1 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102612376A (zh) * | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
AU2011208625C1 (en) * | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
KR102434075B1 (ko) | 2012-05-17 | 2022-08-19 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
US20150250882A1 (en) * | 2012-10-17 | 2015-09-10 | Novo Nordisk Health Care Ag | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery |
WO2014166836A1 (en) | 2013-04-05 | 2014-10-16 | Novo Nordisk A/S | Growth hormone compound formulation |
WO2015036553A1 (en) | 2013-09-16 | 2015-03-19 | Novo Nordisk Health Care Ag | Thiol functionalized polymers |
ES2869309T3 (es) * | 2013-12-13 | 2021-10-25 | Novo Nordisk Healthcare Ag | Método para la conjugación de proteínas con tioéter |
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
CU20170093A7 (es) * | 2015-01-23 | 2017-09-06 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
SI3348635T1 (sl) | 2015-09-08 | 2021-08-31 | Jcr Pharmaceuticals Co., Ltd. | Novi mutant humanega serumskega albumina |
US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
CA2998528A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
WO2017159540A1 (ja) | 2016-03-14 | 2017-09-21 | Jcrファーマ株式会社 | 血清アルブミン-20k成長ホルモン融合タンパク質 |
US20240132566A1 (en) | 2019-10-16 | 2024-04-25 | Jcr Pharmaceuticals Co., Ltd. | Method for producing fusion protein of serum albumin and growth hormone |
US20220378882A1 (en) | 2019-10-30 | 2022-12-01 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone |
CN115845079B (zh) * | 2022-11-24 | 2023-07-18 | 武汉禾元生物科技股份有限公司 | 一种重组人血清白蛋白与重组人生长激素的偶联物及其制备方法 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
EP0355460B1 (en) | 1988-08-24 | 2000-12-27 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization |
US5079230A (en) * | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
CA2345497A1 (en) | 1988-10-28 | 1990-04-28 | Genentech, Inc. | Growth hormone variants and method for forming growth hormone variants |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
EP0464022B1 (en) | 1989-03-20 | 2000-05-31 | The General Hospital Corporation | Insulinotropic hormone |
US5101018A (en) | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
DK0458064T3 (da) * | 1990-05-04 | 1998-04-27 | American Cyanamid Co | Stabilisering af somatotropiner ved modificering af cysteinrester |
JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
JP3267293B2 (ja) | 1990-12-03 | 2002-03-18 | ジェネンテク,インコーポレイテッド | 改変された結合性を有する変異タンパク質の豊富化法 |
IT1251895B (it) | 1991-09-27 | 1995-05-26 | Eniricerche Spa | Mutanti dell'ormone della crescita umano e loro impiego |
EP0555649B1 (en) | 1992-01-14 | 2004-12-08 | Ajinomoto Co., Inc. | Gene encoding transglutaminase derived from fish |
CA2337745C (en) | 1992-07-31 | 2005-04-12 | Genentech, Inc. | Human growth hormone aqueous formulation |
ZA936811B (en) | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5736356A (en) | 1994-01-28 | 1998-04-07 | Ajinomoto Co., Inc. | Transglutaminase originating from Crassostrea gigas |
WO1996006931A1 (en) | 1994-08-26 | 1996-03-07 | Novo Nordisk A/S | Microbial transglutaminases, their production and use |
WO1996010089A1 (fr) | 1994-09-29 | 1996-04-04 | Ajinomoto Co., Inc. | Modification d'un peptide et d'une proteine |
DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
DE69629719T2 (de) | 1995-01-19 | 2004-07-08 | Novozymes A/S | Transglutaminasen aus oomyzeten |
JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
CA2230492C (en) | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
EP0929576A1 (en) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
WO1998013381A1 (fr) | 1996-09-26 | 1998-04-02 | Ajinomoto Co., Inc. | Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant |
US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
JPH1156378A (ja) | 1997-06-11 | 1999-03-02 | Nippon Chem Res Kk | 変異型ヒト成長ホルモンとその用途 |
DE69841063D1 (de) | 1997-06-25 | 2009-09-24 | Merck Serono Sa Coinsins | Disulfid-vernetzte Glycoprotein-Hormone, ihre Herstellung und Verwendung |
CA2296770A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
JPH1192499A (ja) | 1997-09-22 | 1999-04-06 | Sumitomo Pharmaceut Co Ltd | ヒト成長ホルモン変異体 |
US6136536A (en) | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
EP1060192A2 (en) | 1998-02-27 | 2000-12-20 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
DE69942307D1 (de) | 1998-02-27 | 2010-06-10 | Novo Nordisk As | N-terminal veränderte glp-1 abkömmlinge |
EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
US6358705B1 (en) | 1998-07-16 | 2002-03-19 | Novo Nordisk A/S | Method of making proteins in transformed yeast cells |
CA2353574C (en) | 1998-12-07 | 2012-05-08 | Zheng Xin Dong | Analogues of glp-1 |
ATE252601T1 (de) | 1999-05-17 | 2003-11-15 | Conjuchem Inc | Lang wirkende insulinotrope peptide |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
AU5805500A (en) | 1999-07-07 | 2001-01-30 | Maxygen Aps | A method for preparing modified polypeptides |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
EP2067488A1 (en) | 2000-04-12 | 2009-06-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2290142T3 (es) | 2000-05-16 | 2008-02-16 | Bolder Biotechnology, Inc. | Metodos para replegamiento de proteinas que contiene residuos de cisteina libre. |
US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
AU2002226897B2 (en) | 2000-12-07 | 2007-10-25 | Eli Lilly And Company | GLP-1 fusion proteins |
AU2002219021A1 (en) * | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
ES2298378T3 (es) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
JP2004537580A (ja) | 2001-08-10 | 2004-12-16 | エピックス メディカル, インコーポレイテッド | 延長された循環半減期を有するポリペプチド結合体 |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
JP2005518786A (ja) | 2001-11-12 | 2005-06-30 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | ヒトにおける成長ホルモン変異とその用途 |
RS53104A (en) | 2001-11-20 | 2006-10-27 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
FR2836382B1 (fr) | 2002-02-28 | 2004-08-13 | Biomerieux Sa | Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
KR20040098063A (ko) | 2002-04-10 | 2004-11-18 | 일라이 릴리 앤드 캄파니 | 위마비의 치료 |
CA2483478A1 (en) | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | Factor vii or viia polypeptide variants |
US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
ES2336563T3 (es) | 2003-02-19 | 2010-04-14 | Ipsen Pharma | Analogos de glp-1. |
EP1625158A2 (en) | 2003-05-09 | 2006-02-15 | Novo Nordisk A/S | Peptides for use in treating obesity |
EP1654004A2 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
SI2932981T1 (sl) | 2003-09-19 | 2021-11-30 | Novo Nordisk A/S | Albumin-vezavni derivati GLP-1 |
JP2007537981A (ja) | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
JP2008502301A (ja) | 2003-10-10 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | ペプチドの抱合 |
EP1704165B1 (en) | 2003-12-18 | 2010-03-17 | Novo Nordisk A/S | Glp-1 compounds |
BRPI0417684A (pt) | 2003-12-18 | 2007-03-20 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
US20070105770A1 (en) | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
CN1909930B (zh) | 2004-01-21 | 2015-12-16 | 诺和诺德医疗保健公司 | 转谷氨酰胺酶介导的肽的接合 |
CA2553040A1 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
DK1740213T3 (da) | 2004-04-07 | 2012-04-10 | Ares Trading Sa | Væskeformulering til væksthormoner |
US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
US20090111730A1 (en) | 2004-07-08 | 2009-04-30 | Novo Nordisk A/S | Polypeptide protracting tags |
WO2006013202A2 (en) | 2004-08-02 | 2006-02-09 | Novo Nordisk Health Care Ag | Conjugation of fvii |
EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
AU2005322019B2 (en) | 2004-12-22 | 2010-08-26 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
JP2008533104A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Glp−1受容体の二量体ペプチドアゴニスト |
CN101128214A (zh) | 2005-03-18 | 2008-02-20 | 诺和诺德公司 | 长效glp-1化合物 |
CA2612794A1 (en) | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
US20090117640A1 (en) | 2005-08-18 | 2009-05-07 | Novo Nordisk Health Care Ag | Transglutaminase Variants with Improved Specificity |
RU2008105545A (ru) | 2005-08-30 | 2009-10-10 | Ново Нордиск Хелс Кеа Аг (Ch) | Жидкие препараты пэгилированного гормона роста |
CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
KR20080108416A (ko) | 2006-01-19 | 2008-12-15 | 암브룩스, 인코포레이티드 | 조절된 면역원성을 갖는 비천연 아미노산 폴리펩티드 |
ES2546282T3 (es) | 2006-02-14 | 2015-09-22 | Novo Nordisk Health Care Ag | Acoplamiento de polipéptidos en el extremo C-terminal |
BRPI0713963A2 (pt) * | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
CA2672267C (en) | 2006-07-27 | 2016-05-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
EP2054435A1 (en) | 2006-08-18 | 2009-05-06 | Novo Nordisk Health Care AG | Transglutaminase variants with improved specificity |
US20080095837A1 (en) | 2006-08-31 | 2008-04-24 | Emisphere Technologies, Inc. | Human growth hormone formulations |
KR101524880B1 (ko) | 2006-08-31 | 2015-06-01 | 노파르티스 아게 | Hgh를 포함하는 경구 전달용 제약 조성물 |
WO2008101240A1 (en) | 2007-02-16 | 2008-08-21 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
GB0716328D0 (en) | 2007-08-21 | 2007-10-03 | Univ Bath | Detection and functionalisation of S-nitrosylated polypeptides |
CN101842109B (zh) | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | 用a-b-c-d-衍生的肽和它们的治疗用途 |
CA2733200A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk Health Care Ag | Conjugated proteins with prolonged in vivo efficacy |
WO2010029107A1 (en) | 2008-09-09 | 2010-03-18 | Novo Nordisk Health Care Ag | Growth hormone conjugate with increased stability |
ES2561208T3 (es) * | 2008-09-12 | 2016-02-25 | Novo Nordisk A/S | Método de acilación de un péptido o una proteína |
CN102292349B (zh) * | 2009-01-22 | 2016-04-13 | 诺沃—诺迪斯克保健股份有限公司 | 稳定的生长激素化合物 |
CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
AU2011208625C1 (en) | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
EP2536434B1 (en) | 2010-02-16 | 2016-04-20 | Novo Nordisk A/S | Purification method |
WO2014166836A1 (en) | 2013-04-05 | 2014-10-16 | Novo Nordisk A/S | Growth hormone compound formulation |
-
2011
- 2011-01-24 AU AU2011208625A patent/AU2011208625C1/en active Active
- 2011-01-24 EP EP11705470.0A patent/EP2525834B1/en active Active
- 2011-01-24 CA CA2787890A patent/CA2787890C/en active Active
- 2011-01-24 CN CN201180015252.6A patent/CN103002918B/zh active Active
- 2011-01-24 RS RSP20191198 patent/RS59459B1/sr unknown
- 2011-01-24 PL PL11705470T patent/PL2525834T3/pl unknown
- 2011-01-24 WO PCT/EP2011/050923 patent/WO2011089255A1/en active Application Filing
- 2011-01-24 SI SI201131785T patent/SI2525834T1/sl unknown
- 2011-01-24 KR KR1020127021413A patent/KR101813595B1/ko active IP Right Grant
- 2011-01-24 TW TW100102456A patent/TWI508737B/zh active
- 2011-01-24 CN CN201180006742.XA patent/CN102834109B/zh not_active Expired - Fee Related
- 2011-01-24 US US13/522,390 patent/US9695226B2/en active Active
- 2011-01-24 JP JP2012549377A patent/JP5875527B2/ja active Active
- 2011-01-24 BR BR112012018116-5A patent/BR112012018116B1/pt active IP Right Grant
- 2011-01-24 RU RU2012134975/10A patent/RU2605627C2/ru active
- 2011-01-24 MX MX2012008000A patent/MX345736B/es active IP Right Grant
-
2012
- 2012-06-24 IL IL220605A patent/IL220605A/en active IP Right Grant
-
2013
- 2013-12-18 US US14/132,919 patent/US8779109B2/en active Active
-
2015
- 2015-10-26 JP JP2015209720A patent/JP2016026204A/ja active Pending
-
2017
- 2017-05-04 US US15/586,960 patent/US20170239362A1/en not_active Abandoned
-
2019
- 2019-03-15 US US16/354,651 patent/US20190203213A1/en not_active Abandoned
- 2019-12-12 US US16/712,651 patent/US20200102568A1/en not_active Abandoned
-
2021
- 2021-05-21 FI FIC20210013C patent/FIC20210013I1/fi unknown
- 2021-05-26 NO NO2021023C patent/NO2021023I1/no unknown
- 2021-07-08 FR FR21C1029C patent/FR21C1029I2/fr active Active
- 2021-08-25 HU HUS2100029C patent/HUS2100029I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2021023I1 (no) | Somapacitan | |
BR112012028556A2 (pt) | Indóis | |
DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
DK3225404T3 (da) | Fluidpatron | |
CR20130111A (es) | Triazina-oxidiazoles | |
DE10170954T8 (de) | Mikrowellendruckgarer | |
DE112011104226A5 (de) | Käfigmutter | |
DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
DE112011101226A5 (de) | Linearwegmesssystem | |
DE112011102080A5 (de) | Kupplungszentralausrücker | |
DK2442899T3 (da) | Rotorskive | |
DK2539163T3 (da) | Dækventil | |
DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
DE112011102711A5 (de) | Hydrostataktor | |
DK2448659T3 (da) | Rotorskive | |
DK2447426T3 (da) | Vaske-WC | |
DE102010019119B8 (de) | Cuttermesser | |
DE112010005518A5 (de) | Dichtungsmanchette | |
DE102010038420A8 (de) | Reinigungungsvorrichtung | |
DK2596072T3 (da) | Bor-forbindelses-suspension | |
DK2521486T3 (da) | Palpometer | |
CO6801789A2 (es) | N-hetarilmetil pirazolilcarboxamidas | |
DE112011101796A5 (de) | Redoxakkumulatoranlage | |
DE102010035554B8 (de) | Fußtüröffner | |
DK2404809T3 (da) | Trækbjælke |